Black Swift Group LLC Sells 1,998 Shares of Eli Lilly and Company (NYSE:LLY)

Black Swift Group LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 27.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,370 shares of the company’s stock after selling 1,998 shares during the period. Eli Lilly and Company accounts for 1.0% of Black Swift Group LLC’s portfolio, making the stock its 19th largest holding. Black Swift Group LLC’s holdings in Eli Lilly and Company were worth $4,757,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Metis Global Partners LLC lifted its position in shares of Eli Lilly and Company by 2.4% during the 3rd quarter. Metis Global Partners LLC now owns 47,210 shares of the company’s stock valued at $41,825,000 after buying an additional 1,108 shares in the last quarter. Curi RMB Capital LLC raised its stake in Eli Lilly and Company by 9.9% during the 3rd quarter. Curi RMB Capital LLC now owns 6,981 shares of the company’s stock worth $6,184,000 after acquiring an additional 628 shares during the period. Wealthstream Advisors Inc. boosted its position in shares of Eli Lilly and Company by 4.2% in the third quarter. Wealthstream Advisors Inc. now owns 1,332 shares of the company’s stock worth $1,180,000 after purchasing an additional 54 shares during the period. Zions Bancorporation N.A. increased its stake in shares of Eli Lilly and Company by 12.1% in the third quarter. Zions Bancorporation N.A. now owns 9,330 shares of the company’s stock worth $8,266,000 after purchasing an additional 1,004 shares in the last quarter. Finally, Bouvel Investment Partners LLC raised its position in shares of Eli Lilly and Company by 0.6% during the 3rd quarter. Bouvel Investment Partners LLC now owns 6,538 shares of the company’s stock valued at $5,792,000 after purchasing an additional 37 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.0 %

Shares of NYSE LLY opened at $812.00 on Thursday. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53. The business has a fifty day moving average price of $888.32 and a 200 day moving average price of $870.29. The stock has a market capitalization of $770.85 billion, a P/E ratio of 87.71, a price-to-earnings-growth ratio of 3.10 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. Equities research analysts expect that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Bank of America cut their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. BMO Capital Markets lifted their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.